Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging

Autor: Marit Muri Holmen, Olav Engebraaten, Anne Fangberget, Knut Håkon Hole, Bjørn Naume, Dag Rune Olsen, Therese Seierstad, Hans-Jørgen Smith, Line Brennhaug Nilsen
Jazyk: angličtina
Rok vydání: 2010
Předmět:
Adult
Gadolinium DTPA
medicine.medical_specialty
medicine.medical_treatment
Contrast Media
Breast Neoplasms
DCE MRI
Neoadjuvant chemotherapy
Sensitivity and Specificity
Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762 [VDP]
Breast cancer
Text mining
Antineoplastic Combined Chemotherapy Protocols
medicine
Effective diffusion coefficient
Humans
Radiology
Nuclear Medicine and imaging
Breast
Pathological
Neoadjuvant therapy
Neuroradiology
Aged
Chemotherapy
business.industry
Ultrasound
Reproducibility of Results
General Medicine
Middle Aged
medicine.disease
Prognosis
Neoadjuvant Therapy
Medical disciplines: 700::Clinical medical disciplines: 750::Radiology and diagnostic imaging: 763 [VDP]
Diffusion Magnetic Resonance Imaging
Treatment Outcome
ADC
Radiology Nuclear Medicine and imaging
Female
Radiology
business
Prediction
Zdroj: European Radiology
ISSN: 1432-1084
0938-7994
Popis: Objective To explore the predictive value of MRI parameters and tumour characteristics before neoadjuvant chemotherapy (NAC) and to compare changes in tumour size and tumour apparent diffusion coefficient (ADC) during treatment, between patients who achieved pathological complete response (pCR) and those who did not. Methods Approval by the Regional Ethics Committee and written informed consent were obtained. Thirty-one patients with invasive breast carcinoma scheduled for NAC were enrolled (mean age, 50.7; range, 37–72). Study design included MRI before treatment (Tp0), after four cycles of NAC (Tp1) and before surgery (Tp2). Data in pCR versus non-pCR groups were compared and cut-off values for pCR prediction were evaluated. Results Before NAC, HER2 overexpression was the single significant predictor of pCR (p=0.006). At Tp1 ADC, tumour size and changes in tumour size were all significantly different in the pCR and non-pCR groups. Using 1.42×10−3 mm2/s as the cut-off value for ADC, pCR was predicted with sensitivity and specificity of 88% and 80%, respectively. Using a cut-off value of 83% for tumour volume reduction, sensitivity and specificity for pCR were 91% and 80%. Conclusion ADC, tumour size and tumour size reduction at Tp1 were strong independent predictors of pCR. publishedVersion
Databáze: OpenAIRE
Externí odkaz: